High-Yield Pulmonology for USMLE Step 3: COPD, Asthma, PE, and Pneumonia
A 62-year-old former smoker rolls into your ED at 2 AM, barely completing sentences, with a pH of 7.28 and a pCO2 of 68. You have about four minutes to nail the management sequence before this goes sideways. That's the energy Step 3 pulmonology questions bring — and honestly, it's the energy of a real night on call. I've watched residents freeze on this exact scenario, not because they didn't know the medicine, but because they never practiced the sequence under pressure.
Let's fix that.
PFTs: The One Skill That Unlocks Half the Pulm Questions
I tell every resident I tutor: if you can read PFTs cold, you can answer roughly 40% of pulmonology items without breaking a sweat. The exam loves handing you a table of values and asking you to sort obstructive from restrictive — then pivot to management.
Obstructive pattern (COPD, asthma, bronchiectasis):
- FEV1/FVC ratio < 0.70 — this is your anchor point
- FEV1 reduced; FVC normal or mildly reduced
- TLC normal or increased (air trapping, especially in emphysema)
- DLCO reduced in emphysema (destroyed alveolar surface area), but normal in asthma — this distinction alone has been a correct-answer differentiator on multiple practice exams I've reviewed
Restrictive pattern (pulmonary fibrosis, sarcoidosis, neuromuscular disease):
- FEV1/FVC ratio normal or elevated — both values drop, but they drop together
- TLC reduced (the lungs literally can't expand)
- DLCO reduced if it's parenchymal disease; normal if it's a chest wall or neuromuscular problem
Here's something that trips people up more than it should: the mixed obstructive-restrictive pattern. You see a reduced FEV1/FVC and a reduced TLC in the same patient. Think combined emphysema plus pulmonary fibrosis, or advanced COPD with superimposed fibrotic changes. It's uncommon in real life but the exam adores it precisely because it demands you understand both patterns rather than just pattern-match one column of numbers.
COPD Exacerbations: The Step 3 Bread and Butter
Getting the Diagnosis Right
COPD requires spirometry confirmation — post-bronchodilator FEV1/FVC < 0.70 with chronic respiratory symptoms and an appropriate exposure history. Step 3 won't usually ask you to diagnose COPD from scratch; they'll tell you the patient has it and throw you straight into an exacerbation. But know the diagnostic criteria cold because occasionally they'll sneak in a vignette where the "COPD patient" actually has something else.
The Exacerbation Management Bundle
The classic stem: worsening dyspnea over 2–3 days, sputum turns green, ABG shows pH 7.31, pCO2 55, PaO2 58. Go.
- Short-acting bronchodilators first, always. Albuterol + ipratropium, nebulized. This isn't controversial — it's reflex.
- Systemic corticosteroids: prednisone 40 mg PO × 5 days. In my experience, residents overthink the dosing. The REDUCE trial showed 5 days works as well as 14 days, with fewer side effects. The exam expects you to know this.
- Antibiotics — but only when indicated. You need at least one Anthonisen criterion: increased dyspnea, increased sputum volume, or sputum purulence. Practically, if the sputum changed color, you're treating. Go with azithromycin, doxycycline, or amoxicillin-clavulanate.
- BiPAP for respiratory acidosis (pH < 7.35 with hypercapnia). This is where the real points live on CCS cases. Starting NIV drops intubation rates and mortality — it's one of the strongest evidence-based interventions in all of pulmonary medicine.
When to intubate: BiPAP failure, hemodynamic instability, inability to protect the airway, or severe acidosis (pH < 7.25) that isn't responding. Don't let a patient sit on BiPAP with a worsening pH because you're afraid to call anesthesia.
Surprising insight: Here's something most review resources skip — oxygen-induced hypercapnia in COPD isn't primarily about "knocking out the hypoxic drive." The bigger mechanism is the Haldane effect (increased O2 displaces CO2 from hemoglobin) and V/Q mismatch worsening from loss of hypoxic vasoconstriction. The exam probably won't quiz you on the mechanism, but understanding it stops you from making the dangerous mistake of withholding oxygen from a hypoxic COPD patient. Target SpO2 88–92%, titrate carefully, but never let someone desaturate because you're scared of CO2 retention.
Asthma: Stepwise Therapy and the Exacerbation You Can't Miss
The Chronic Management Ladder
Step 3 tests whether you know when to step up and — just as importantly — when to step down.
| Step | Preferred Treatment |
|---|---|
| 1 (intermittent) | SABA prn only |
| 2 (mild persistent) | Low-dose ICS |
| 3 (moderate persistent) | Low-dose ICS + LABA |
| 4 (moderate-severe persistent) | Medium-dose ICS + LABA |
| 5–6 (severe persistent) | High-dose ICS + LABA ± oral corticosteroids or biologic (omalizumab, dupilumab, mepolizumab) |
One thing I hammer home: a LABA should never be used alone without an ICS in asthma. This was a black-box warning issue for years (SMART trial, Salmeterol), and the exam still tests it. COPD is different — you can use a LABA monotherapy there. But in asthma? ICS is always the backbone.
Acute Exacerbation Management
- Mild-moderate: Albuterol q20 min × 3 doses + systemic corticosteroids (prednisone 40–60 mg or IV methylprednisolone) + supplemental O2 to maintain SpO2 > 93%
- Severe (talking in single words, accessory muscle use, PEFR < 40% predicted): Continuous albuterol nebulization + IV magnesium sulfate 2g over 20 minutes + ipratropium. The magnesium is a smooth muscle relaxant and genuinely reduces hospitalization rates — don't forget it under pressure.
- Status asthmaticus / impending respiratory failure: Prepare for intubation. Heliox (helium-oxygen mixture) can occasionally buy time by reducing airway resistance, but don't delay definitive management hoping it'll work.
Contrarian take: Most Step 3 prep courses spend enormous time drilling the stepwise therapy table, and I get it — it's testable. But in my experience, the questions that actually separate passers from high-scorers are the acute management scenarios, especially the CCS cases where you have to sequence interventions in real time. I've seen residents who had the stepwise table memorized backward still fumble a status asthmaticus CCS because they forgot IV magnesium, or they ordered a chest X-ray before starting bronchodilators. Spend 60% of your pulm study time on acute scenarios, not the chronic table. You already know the table. Practice the emergencies.
Pulmonary Embolism: From Wells Score to Lysis
Diagnosis: Know Your Pre-test Probability
Wells criteria are the gateway — the exam expects you to stratify before ordering anything:
- Low probability (Wells < 2): Start with D-dimer. If negative, PE is effectively ruled out. If positive, proceed to CTPA. This sequential approach is critical — going straight to CTPA on a low-probability patient is wasteful and, on the exam, probably the wrong answer.
- High probability (Wells ≥ 5): Skip the D-dimer entirely and go straight to CTPA. A negative D-dimer in a high-probability patient is unreliable enough that it shouldn't change your management.
CTPA remains the gold standard. V/Q scan is the backup for patients who can't get contrast (renal failure, severe contrast allergy).
Treatment Stratified by Severity
This is where Step 3 gets surgical. The management changes dramatically based on hemodynamic status:
Massive PE (systolic BP < 90, cardiac arrest, or persistent hypotension):
- Systemic thrombolytics — alteplase 100 mg IV over 2 hours. This is one of the few situations in medicine where the answer is lytics before you even finish the workup, if the clinical picture is clear. Absolute contraindications still apply (active bleeding, recent intracranial surgery, hemorrhagic stroke).
- If thrombolytics are contraindicated: surgical embolectomy or catheter-directed therapy. The exam loves presenting the patient with a recent surgery who can't get tPA.
Submassive PE (hemodynamically stable but RV strain on echo or CT):
- Anticoagulation + close monitoring in an ICU or step-down unit. If they deteriorate, escalate to thrombolytics. This is a nuanced gray zone — the exam tests whether you jump to lytics too early or wait appropriately.
Low-risk PE (stable, no RV strain, low PESI score):
- Anticoagulation alone. DOACs are preferred — rivaroxaban 15 mg BID × 21 days then 20 mg daily, or apixaban 10 mg BID × 7 days then 5 mg BID. No bridging with heparin needed for these two, which is a detail the exam loves.
- Outpatient management is appropriate for truly low-risk patients. Don't hospitalize everyone.
Duration of anticoagulation:
- Provoked PE (surgery, immobilization, oral contraceptives): 3 months, then stop
- Unprovoked PE or persistent risk factor (active cancer, thrombophilia): at least 3 months, strongly consider indefinite therapy with periodic reassessment
Surprising insight: Here's a pearl that catches even senior residents off guard — submassive PE patients who get thrombolytics don't have better mortality at 90 days compared to anticoagulation alone (PEITHO trial). They do have less hemodynamic decompensation, but they bleed more. That's why the answer for a stable submassive PE is almost always "anticoagulate and watch," not "lyse." The exam tests this restraint.
Pneumonia: Pick the Right Antibiotic on the First Try
Community-Acquired Pneumonia (CAP)
I've seen this tested a dozen different ways, but the core decision tree hasn't changed much since the 2019 ATS/IDSA guidelines:
Outpatient, healthy, no comorbidities:
- Amoxicillin 1g TID × 5 days — this is the preferred first-line, and it surprises people who default to azithromycin
- OR doxycycline 100 mg BID
- OR azithromycin (only if local macrolide resistance is < 25%, which honestly rules out most of the US at this point)
Outpatient with comorbidities (diabetes, COPD, heart failure, renal disease, alcoholism):
- Respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) × 5 days
- OR beta-lactam (amoxicillin-clavulanate 2g BID, or ceftriaxone) + macrolide
Inpatient, non-ICU:
- Beta-lactam (ceftriaxone 1–2g IV daily, or ampicillin-sulbactam) + azithromycin
- OR respiratory fluoroquinolone monotherapy
ICU-level CAP:
- Beta-lactam + azithromycin (the workhorse combo)
- OR beta-lactam + respiratory fluoroquinolone
- Add vancomycin or linezolid for MRSA coverage if: necrotizing pneumonia, post-influenza pneumonia, or known MRSA colonization. This is a common CCS add-on that people forget.
Atypical Pneumonia: The Pattern Recognition Game
The exam loves these vignettes because they reward clinical pattern recognition over rote memorization:
| Organism | What Makes You Think of It |
|---|---|
| Mycoplasma pneumoniae | Young adult (18–30), dry cough, "walking pneumonia," bilateral interstitial infiltrates on CXR, cold agglutinins, maybe a bullous myringitis |
| Legionella pneumophila | Hyponatremia + diarrhea/GI symptoms, recent hotel stay or hospital water exposure, Gram stain shows PMNs but no organisms, urine antigen positive |
| Chlamydophila pneumoniae | Gradual onset, preceded by hoarseness and sore throat, often in young adults — the "two-phase illness" |
Quick clinical tip: if the vignette mentions hyponatremia in a pneumonia patient, your ears should perk up for Legionella. It's almost Pavlovian at this point — and the test-writers know you know it, which means they'll sometimes use it as a distractor. Read carefully.
Pleural Effusion: Light's Criteria in 30 Seconds
You'll get a thoracentesis result and need to classify it. Light's criteria define an exudate if ANY of the following are met:
- Pleural protein / serum protein > 0.5
- Pleural LDH / serum LDH > 0.6
- Pleural LDH > 2/3 the upper limit of normal serum LDH
If none are met, it's a transudate — think heart failure, cirrhosis, nephrotic syndrome. Treat the underlying condition.
If it's an exudate, dig deeper: infection (empyema, TB), malignancy, PE, rheumatologic disease. Check cell count, glucose, pH, cytology, and cultures.
One nuance worth knowing: patients on diuretics can have a transudate that "looks like" an exudate on Light's criteria because diuresis concentrates the pleural fluid protein. If the clinical picture screams transudate (bilateral effusions, known CHF, no fever), check the serum-to-pleural albumin gradient — if it's > 1.2 g/dL, it's still likely a transudate despite meeting Light's criteria.
Frequently Asked Questions
How many pulmonology questions should I expect on Step 3?
Pulmonary medicine typically accounts for 8–12% of the exam content, but the impact is outsized because pulm cases show up heavily in the CCS portion. In my experience, you'll see at least 2–3 CCS cases involving acute respiratory scenarios — COPD exacerbations, PE management, or pneumonia with clinical deterioration. These cases are among the highest-yield for your time.
Should I memorize the GOLD classification for COPD?
Know the basic framework (GOLD grades 1–4 based on FEV1, groups A–E based on exacerbation history), but don't burn hours memorizing every inhaler combination. Step 3 overwhelmingly tests acute exacerbation management and the decision to start NIV. I've reviewed hundreds of practice questions, and the chronic COPD maintenance regimen is tested far less frequently than the exacerbation bundle.
What's the most commonly tested PE scenario on Step 3?
The hemodynamically unstable patient where the answer is thrombolytics. The exam wants to know that you won't hesitate when someone is crashing — alteplase 100 mg IV over 2 hours. The second most common: the stable patient with a low Wells score where the correct first step is D-dimer, not CTPA. Both test decision-making under uncertainty, which is the whole point of Step 3.
When do I add MRSA coverage in pneumonia?
Three situations: necrotizing or cavitary pneumonia, post-influenza bacterial superinfection, and known MRSA colonization or recent MRSA infection. If the vignette describes a patient who had influenza last week and now has a new fever with a rapidly progressing infiltrate, that's your cue. Vancomycin 15–20 mg/kg IV q8–12h or linezolid 600 mg IV/PO q12h.
Is the BiPAP threshold for COPD exacerbation pH < 7.35 or pH < 7.30?
Start BiPAP at pH < 7.35 with hypercapnia. Don't wait until 7.30 — by then you've lost valuable time. The evidence for NIV in acute hypercapnic respiratory failure is strongest when initiated early. If the pH is < 7.25 and not improving with BiPAP, that's your intubation trigger.
Put It Into Practice
The difference between reading about pulmonology and being ready for Step 3 is active recall under time pressure. Step3Sim offers free USMLE Step 3 practice questions covering pulmonology and every other organ system — with CCS-style cases that force you to sequence your decisions, not just pick from a list.